Gastroenterology
|
On-Demand Webcast 2 Expert Perspectives on Hepatitis B Virus and the Infected Patient |
Expert Perspectives on Hepatitis B
| |
| Dear Colleague, |
|
| Left unhalted, replication of hepatitis B virus (HBV) can have serious consequences, including cirrhosis or hepatocellular carcinoma. Persons with risk factors for this highly contagious virus must be screened, and those who are infected should be thoroughly evaluated to determine candidacy for treatment. |
|
| If you missed the CME/CE audioconference held on November 8, 2006, here is your second chance to participate in this outstanding educational activity. This 1-hour webcast will provide you with a solid overview of the virus, including its structure and replication, genotypes, and natural history and talk about how to make optimal use of available screening and diagnostic tools, as well as how to apply recently updated management guidelines to determine which patients are candidates for treatment. |
|
| I hope you find this activity helpful in applying current knowledge of hepatitis B and its management in the care of your patients. |
|
| Sincerely, | |
| top |
|
TARGET AUDIENCE |
|
| This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection. | |
ACTIVITY GOAL |
|
| The goal of Expert Perspectives on Hepatitis B Virus and the Infected Patient is to examine current knowledge about the hepatitis B virus (HBV) and current strategies for diagnosing and evaluating infected patients. | |
LEARNING OBJECTIVES |
|
|
|
| top | |
CME INFORMATION—PHYSICIANS |
|
Statement of Accreditation |
|
| Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. | |
Credit Designation |
|
| Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies. |
|
CME INFORMATION—PHYSICIAN ASSISTANTS |
|
| Projects In Knowledge will issue a certificate of participation for each course the participant completes. Please check with your organization and/or society for reciprocity. | |
CE INFORMATION—NURSES |
|
| This activity has been approved by the American Association of Critical-Care Nurses (AACN) for a maximum of 1.0 contact hour. Provider #00012705. | |
|
|
| top | |
DISCLOSURE INFORMATION |
|
| The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. | |
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR). |
|
Adrian M. Di Bisceglie, MD, FACP, has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Chiron Corporation, Metabasis Therapeutics, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb Company, Gilead Sciences, Inc, and Roche Pharmaceuticals; and is a member of advisory boards for Bristol-Myers Squibb Company, Idenix Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated. |
|
Michael W. Fried, MD, has received grant/research support from, is a consultant for, and is a member of advisory boards for GlaxoSmithKline, Idenix Pharmaceuticals Inc, Roche Pharmaceuticals, and Valeant Pharmaceuticals International. |
|
Peer Reviewer has disclosed no significant relationships. |
|
Projects In Knowledge's staff members have no significant relationships to disclose. |
|
This CME/CE activity will include a discussion of the unlabeled/unapproved uses of hepatitis A vaccine, hepatitis B vaccine, a discussion of combination hepatitis A and B vaccine, interferon alfa-2a, and peginterferon alfa-2b. |
|
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. |
|
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. |
|
This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient. |
|
This independent CME/CE activity is supported by an educational grant from Bristol-Myers Squibb Company. | |
| top
1765 |
|
|
|
